ARGX - argenx SE

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
102.04
-1.05 (-1.02%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close103.09
Open102.06
Bid90.00 x 800
Ask125.00 x 800
Day's Range101.77 - 103.40
52 Week Range63.81 - 114.84
Volume173,459
Avg. Volume239,708
Market Cap3.594B
Beta (3Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-1.73
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est145.91
Trade prices are not sourced from all markets
  • Benzinga25 days ago

    6 Valuable Pipeline Drugs With Upcoming Catalysts

    Heading into December, biotech stocks held up fairly well in 2018. Evaluate Pharma , a firm specializing in data-driven news and analysis in biotech, compiled a list of blockbuster drugs in the works with ...

  • Reuters2 months ago

    Dutch firm argenx, J&J affiliate to collaborate on cancer therapy

    Netherlands-based biopharmaceutical company argenx SE said it signed a deal with Cilag GmbH International, an affiliate of Johnson & Johnson's Janssen Pharmaceutical Companies unit, to develop its Cusatuzumab drug in certain types of cancer. The deal, which is potentially worth up to $1.6 billion, represents a global collaboration and licensing agreement for the cancer drug Cusatuzumab, the company said. Janssen will pay argenx $300 million in upfront cash payment, while Johnson & Johnson Innovation will make an equity investment of $200 million in argenx, the company said.

  • GlobeNewswire2 months ago

    argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia

    Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced  that it will share the detailed data from its Phase 2 clinical trial of efgartigimod (ARGX-113) in immune thrombocytopenia (ITP)  and the Phase 1 portion of its Phase 1/2 clinical trial of cusatuzumab (ARGX-110) in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) during a workshop being held in conjunction with the 60th American Society of Hematology (ASH) Annual Meeting and Exposition. The workshop is being held on Monday, December 3, 2018 at 12:00 p.m. PT.

  • GlobeNewswire3 months ago

    argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition

    Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced updated data from the ongoing Phase 1 dose-escalation part of its Phase 1/2 clinical trial of cusatuzumab (ARGX-110) in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). As of the data cut-off on July 16, 2018, a 92% (11/12 patients) overall response rate (ORR) was observed, with 42% of patients achieving minimal residual disease (MRD) negativity. Data from this ongoing AML trial are expected to be further updated, including ORR and duration of response, during a company workshop to be held around the American Society of Hematology (ASH) Annual Meeting.

  • Simply Wall St.3 months ago

    Is argenx SE’s (EBR:ARGX) Liquidity Good Enough?

    Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like argenx SE (EBR:ARGX), with a market cap of €2.5b, are often out of the spotlight. Read More...

  • GlobeNewswire3 months ago

    argenx reports third quarter 2018 financial results and provides business update

    October 25, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of.

  • GlobeNewswire4 months ago

    argenx announces closing of U.S. public offering for gross proceeds of approximately $300.6 million

    Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the closing of its public offering in the United States and an offering in Europe only to qualified investors (within the meaning of Directive 2003/71/EC, as amended) (the Offering) of 3,475,000 American Depositary Shares (ADSs) at a price to the public of $86.50 per ADS, for gross proceeds of approximately $300.6 million, before deducting underwriting discounts and commissions and offering expenses payable by argenx. Each of the ADSs offered represents the right to receive one ordinary share, nominal value of €0.10 per share.

  • GlobeNewswire4 months ago

    argenx raises approximately $300.6 million in gross proceeds in a U.S. public offering

    Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the pricing of an underwritten public offering in the United States and an offering in Europe only to qualified investors (within the meaning of Directive 2003/71/EC, as amended) (the Offering) with anticipated gross proceeds totalling approximately $300.6 million from the sale of 3,475,000 American Depositary Shares (ADSs) at a price to the public of $86.50 per ADS. Each of the ADSs offered represents the right to receive one ordinary share, nominal value of €0.10 per share. All of the ADSs in the Offering are being sold by argenx.

  • Benzinga4 months ago

    The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares

    The following are top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 17.) Champions Oncology Inc (NASDAQ: CSBR ) Emergent Biosolutions ...

  • GlobeNewswire4 months ago

    argenx announces launch of proposed public offering in the United States

    Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that it has commenced an underwritten U.S. public offering of American Depositary Shares (ADSs) and an offering of ADSs in Europe only to qualified investors (within the meaning of Directive 2003/71/EC, as amended) (the Offering). Each of the ADSs offered in the Offering represents the right to receive one ordinary share, nominal value of €0.10 per share.

  • GlobeNewswire4 months ago

    argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia

    Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) today announced positive topline results from its Phase 2 proof-of-concept clinical trial of efgartigimod (ARGX-113) in adult primary immune thrombocytopenia (ITP) patients. The Phase 2 data of efgartigimod showed a favorable safety and tolerability profile consistent with the Phase 1 healthy volunteer trial and the Phase 2 proof-of-concept trial in generalized myasthenia gravis (gMG).

  • GlobeNewswire4 months ago

    argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis

    Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the dosing of the first patient in a global Phase 3 registration trial of efgartigimod (ARGX-113) in patients with generalized myasthenia gravis (gMG). "The dosing of the first patient represents an important milestone in advancing efgartigimod towards registration with the hopes of providing more therapeutic options for gMG patients globally. With planned enrollment of 150 patients, this will be the broadest trial of its kind in gMG, and the first to address both acetylcholine receptor (AChR) autoantibody positive as well as AChR autoantibody negative patients like those with MuSK MG," commented Nicolas Leupin, CMO of argenx.

  • GlobeNewswire5 months ago

    argenx receives feedback from Japan's PMDA on Phase 3 clinical trial and regulatory pathway for efgartigimod in generalized myasthenia gravis

    Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced it has received feedback from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan on the design of a Phase 3 trial and regulatory pathway towards potential marketing authorization of efgartigimod (ARGX-113) in patients with generalized myasthenia gravis (gMG). Based on feedback from the PMDA, argenx expects the data from the planned global Phase 3 registration trial, if positive, will serve as the basis to submit for marketing authorization in Japan.

  • Benzinga5 months ago

    Argenx Shares Up After AbbVie Exercises Option To License Immuno-Oncology Drug

    Shares of Netherlands-based biotech argenx SE – ADR (NASDAQ: ARGX ) were trading up Wednesday following an announcement concerning its immuno-oncology antibody AGRX-115. What Happened Argenx said AbbVie ...

  • Reuters5 months ago

    AbbVie doubles down on cancer project with biotech group Argenx

    Biotech group Argenx (ARGX.BR) said on Wednesday U.S. pharma group AbbVie (ABBV.N) had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million(490.08 million pounds). It is also developing a cancer immunotherapy drug named ARGX-115 with AbbVie, for which the U.S. company has now decided to trigger an option which gives it an exclusive licence to develop and commercialise the drug. ARGX-115 is in pre-clinical development, meaning it still has several stages of clinical trials to pass before it could enter the market.

  • GlobeNewswire5 months ago

    argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody

    Breda, the Netherlands/Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the exercise by AbbVie of its exclusive license option to develop and commercialize ARGX-115, an antibody targeting the novel immuno-oncology target glycoprotein A repetitions predominant (GARP). "We are very excited by AbbVie`s decision to exercise its option to license and develop ARGX-115, given its compelling track record in oncology.

  • GlobeNewswire6 months ago

    argenx reports second quarter business update and half-year 2018 financial results

    Management to host conference call today at 3 p.m. CEST / 9 a.m. EDT August 2, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing ...

  • GlobeNewswire6 months ago

    argenx to host conference call & webcast to report second quarter business update and half year 2018 financial results on August 2, 2018

    Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced it will host a conference call and audio webcast on Thursday, August 2, 2018 at 3:00 p.m. CEST (9:00 a.m. EDT) to discuss financial results for the first half of 2018 and to provide a second quarter business update. To participate in the conference call, please select your phone number below, and use the confirmation code 7669735.

  • GlobeNewswire6 months ago

    argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation

    Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the publication in the Journal of Clinical Investigation (JCI) of the full study results from the Phase 1 study of FcRn-antagonist efgartigimod (ARGX-113) in healthy volunteers. "The Phase 1 data published today in the peer-reviewed Journal of Clinical Investigation highlight the unique design of efgartigimod as an Fc fragment modified by our proprietary ABDEG(TM) technology.  The drug candidate`s binding properties with FcRn are enhanced by the ABDEG mutation, which may contribute to the differentiated pharmacokinetic and pharmacodynamic activity we saw in the Phase 1 study, as well as its favorable tolerability profile," said Nicolas Leupin, CMO of argenx.

  • GlobeNewswire6 months ago

    argenx receives milestone payment from strategic collaboration with Shire

    Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it has reached a preclinical milestone in its strategic collaboration with Shire plc. The milestone, for which an undisclosed payment has been received, was triggered by Shire exercising its exclusive option to in-license an antibody discovered and developed using the Company`s proprietary SIMPLE Antibody(TM) platform and Fc engineering technologies. "The exclusive option exercised by Shire is a testament to the power of our antibody platform and the excellent progress we have made in our strategic collaboration, discovering highly differentiated SIMPLE antibodies against select novel targets," said Hans de Haard, Chief Scientific Officer of argenx.

  • GlobeNewswire7 months ago

    argenx receives second preclinical milestone payment under its development agreement with AbbVie

    Breda, the Netherlands/Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the achievement of the second of two preclinical milestones towards an investigational new drug (IND) filing for ARGX-115, triggering a further $ 10 million payment from AbbVie. In April 2016, argenx entered into a development and exclusive license option agreement with AbbVie to develop and commercialize ARGX-115. Over the course of the past two years, argenx has been eligible to receive two preclinical milestones of $ 10 million each.